Exploring the natural history of atherosclerosis with intravascular ultrasound

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 2, 2007, Pages 295-306

  Nicholls, Stephen J ^a   Andrews, Jordan ^a   Moon, Keon Woong ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Imaging; Intravascular ultrasound; Risk factors

Indexed keywords

AMLODIPINE; ANTICOAGULANT AGENT; ATORVASTATIN; AVASIMIBE; AZATHIOPRINE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ENALAPRIL; ETC 216; EVEROLIMUS; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PACTIMIBE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSUVASTATIN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONVENTIONAL ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG COMPETITION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; INTRAVASCULAR ULTRASOUND; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; PREVALENCE; QUANTITATIVE DIAGNOSIS; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASOSPASM;

ATHEROSCLEROSIS; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33947709308     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.2.295     Document Type: Review

References (106)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
2. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 68, 939-950 (1983).
3. Ambrose JA, Tannenbaum MA, Alexopoulos D et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12, 56-62 (1988).
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 92, 657-671 (1995).
5. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92, 2333-2342 (1995).
6. Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am. J. Cardiol. 82, 5M-11M (1998).
7. Bots ML, Hoes AW, Koudstaal PJ, Hofman A. Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432-1437 (1997).
8. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483-494 (1997).
9. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262-269 (1998).
10. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
11. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
12. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
13. Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation 104, 68-73 (2001).
14. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 103, 2171-2175 (2001).
15. Polak JF, Shemanski L, O'Leary DH et al. Hypoechoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology 208, 649-654 (1998).
16. Bom N, Lancee CT, Van Egmond FC. An ultrasonic intracardiac scanner. Ultrasonics 10, 72-76 (1972).
17. Guedes A, Keller PF, L'Allier PL, Lesperance J, Gregoire J, Tardif JC. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 45, 559-564 (2005).
18. Ramasubbu K, Schoenhagen P, Balghith MA et al. Repeated intravascular ultrasound imaging in cardiac transplant recipients does not accelerate transplant coronary artery disease. J. Am. Coll. Cardiol, 41, 1739-1743 (2003).
19. Mintz GS, Painter JA, Pichard AD et al. Atherosclerosis in angiographically "normal" coronary artery reference segments: an intravascular ultrasound study with clinical correlations. J. Am. Coll. Cardiol. 25, 1479-1485 (1995).
20. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371-1375 (1987).
21. Schoenhagen P, Ziada KM, Vince DG, Nissen SE, Tuzcu EM. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J. Am. Coll. Cardiol. 38, 297-306 (2001).
22. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101, 598-603 (2000).
23. Schoenhagen P, Vince DG, Ziada KM et al. Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. Am. J. Cardiol. 89, 1354-1359 (2002).
24. Tuzcu EM, Kapadia SR, Tutar E et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103, 2705-2710 (2001).
25. Joseph A, Ackerman D, Talley JD, Johnstone J, Kupersmith J. Manifestations of coronary atherosclerosis in young trauma victims - an autopsy study. J. Am. Coll. Cardiol. 22, 459-467 (1993).
26. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler. Thromb. 13, 1291-1298 (1993).
27. Berenson GS, Wattigney WA, Tracy RE et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am. J. Cardiol. 70, 851-858 (1992).
28. Rioufol G, Finer G, Ginon I et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 106, 804-808 (2002).
29. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr. Opin. Cardiol. 14, 140-150 (1999).
30. Mintz GS, Kent KM, Pichard AD, Popma JJ, Satler LF, Leon MB. Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Cardiol. Clin. 15, 17-29 (1997).
31. Fuessl RT, Hoepp HW, Sechtem U. Intravascular ultrasonography in the evaluation of results of coronary angioplasty and stenting. Curr. Opin. Cardiol. 14, 471-479 (1999).
32. Serruys PW, Degertekin M, Tanabe K et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 109, 627-633 (2004).
33. Mintz GS, Nissen SE, Anderson WD et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 37, 1478-1492 (2001).
34. Nicholls SJ, Sipahi I, Schoenhagen P et al. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferasc Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am. Heart J. 152, 67-74 (2006).
35. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or = 12 months) follow-up intravascular ultrasound. Circulation 108, 2757-2762 (2003).
36. von Birgelen C, Hartmann M, Mintz GS et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110, 1579-1585 (2004).
37. Nicholls SJ, Tuzcu EM, Crowe T et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J. Am. Coll. Cardiol. 47, 1967-1975 (2006).
38. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714 (1977).
39. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. 60, 455-461 (1989).
40. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234-1241 (1990).
41. Rong JX, Li J, Reis ED et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104, 2447-2452 (2001).
42. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA. 91, 9607-9611 (1994).
43. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
44. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66, 892-900 (1980).
45. Chiesa G, Monteggia E, Marchesi M et al. Recombinant Apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. 90, 974-980 (2002).
46. Shah PK, Nilsson J, Kaul S et al. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97, 780-785 (1998).
47. Shah PK, Yano J, Reyes O et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 103, 3047-3050 (2001).
48. Nicholls SJ, Tuzcu EM, Sipahi I et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J. Am. Coll. Cardiol. 47, 992-997 (2006).
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
50. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
51. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
52. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998).
53. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
54. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301-1307 (1995).
55. Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J. Effects of statins on vascular structure and function: a systematic review. Am. J. Med. 117, 775-790 (2004).
56. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
57. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005).
58. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
59. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
60. Nicholls SJ, Tuzcu EM, Sipahi I et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am. J. Cardiol. 97, 1553-1557 (2006).
61. Matsuzaki M, Hiramori K, Imaizumi T et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low density lipoprotein-Apheresis Coronary Morphology And Reserve Trial (LACMART). J. Am. Coll. Cardiol. 40, 220-227 (2002).
62. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
63. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2572 (2003).
64. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217-2225 (2004).
65. Sipahi I, Tuzcu EM, Schoenhagen P et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J. Am. Coll. Cardiol. 48, 833-838 (2006).
66. Rudel LL, Lee RG, Parini P. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 25, 1112-1118 (2005).
67. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 137, 77-85 (1998).
68. Asami Y, Yamagishi I, Akiyoshi K, Tomoike H, Tsuchida K, Higuchi S. Inhibitory effect of TS-962 on the formation of early atherosclerotic lesions in high fat-fed hyperlipidemic hamsters. Atherosclerosis 146, 237-242 (1999).
69. Chiwata T, Aragane K, Fujinami K et al. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Br. J. Pharmacol. 133, 1005-1012 (2001).
70. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 103, 2604-2609 (2001).
71. Delsing DJ, Offerman EH, van Duyvenvoorde W et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholestcrol-lowering effect in ApoE*3-Leiden mice. Circulation 103, 1778-1786 (2001).
72. Rival Y, Junquero D, Bruniquel F et al. Anti-atherosclerotic properties of the acyl-coenzyme A:cholesterol acyltransferase inhibitor F 12511 in casein-fed New Zealand rabbits. J. Cardiovasc. Pharmacol. 39, 181-191 (2002).
73. Tardif JC, Gregoire J, l'Allier PL et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110, 3372-3377 (2004).
74. Sahi J, Milad MA, Zheng X et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther. 306, 1027-1034 (2003).
75. Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354, 1253-1263 (2006).
76. Feng B, Yao PM, Li Y et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell. Biol. 5, 781-792 (2003).
77. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349, 847-858 (2003).
78. Bekeredjian R, Hardt S, Just A, Hansen A, Kuecherer H. Influence of catheter position and equipment-related factors on the accuracy of intravascular ultrasound measurements. J. Invasive Cardiol. 11, 207-212 (1999).
79. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
80. Aikawa M, Rabkin E, Sugiyama S et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103, 276-283 (2001).
81. Nicholls SJ, Cutri B, Worthley SC et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 25, 2416-2421 (2005).
82. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteases, and cell death in human carotid plaques. Circulation 103, 926-933 (2001).
83. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106, 2200-2206 (2002).
84. Rodriguez-Granillo GA, Garcia-Garcia HM, Mc Fadden EP et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J. Am. Coll. Cardiol. 46, 2038-2042 (2005).
85. Rodriguez-Granillo CA, Garcia-Garcia HM, Valgimigli M et al. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. Eur. Heart J. 27, 1921-1927 (2006).
86. Schaar JA, Regar E, Mastik F et al. Incidence of high-strain patterns in human coronary arteries: assessment with three-dimensional intravascular palpography and correlation with clinical presentation. Circulation 109, 2716-2719 (2004).
87. MacNeill BD, Jang IK, Bouma BE et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J. Am. Coll. Cardiol. 44, 972-979 (2004).
88. Tearney GJ, Yabushita H, Houser SL et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation 107, 113-119 (2003).
89. Kawasaki M, Takatsu H, Noda T et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 105, 2487-2492 (2002).
90. Kawasaki M, Sano K, Okubo M et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J. Am. Coll. Cardiol. 45, 1946-1953 (2005).
91. Leber AW, Becker A, Knez A et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J. Am. Coll. Cardiol. 47, 672-677 (2006).
92. Worthley SG, Helft G, Fuster V et al. A novel nonobstructive intravascular MRI coil: in vivo imaging of experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 346-350 (2003).
93. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291, 210-215 (2004).
94. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch. Intern. Med. 164, 1285-1292 (2004).
95. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 228, 826-833 (2003).
96. Achenbach S, Ropers D, Pohle FK et al. Detection of coronary artery stenoses using multi-detector CT with 16×0.75 collimation and 375 ms rotation. Eur. Heart J. 26, 1978-1986 (2005).
97. Salm LP, Bax JJ, Jukema JW et al. Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography. Am. Heart J. 150, 775-781 (2005).
98. Fayad ZA, Fuster V, Fallon JT et al. Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation 102, 506-510 (2000).
99. Fayad ZA, Nahar T, Fallon JT et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 101, 2503-2509 (2000).
100. Saam T, Ferguson MS, Yarnykh VL et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol. 25, 234-239 (2005).
101. Choudhury RP, Fuster V, Badimon JJ, Fisher EA, Fayad ZA. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arterioscler. Thromb. Vasc. Biol. 22, 1065-1074 (2002).
102. Corti R, Fayad ZA, Fuster V et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104, 249-252 (2001).
103. Corti R, Fuster V, Fayad ZA et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
104. Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110, 2336-2341 (2004).
105. Yonemura A, Momiyama Y, Fayad ZA et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J. Am. Coll. Cardiol. 45, 733-742 (2005).
106. Corti R, Osende JI, Fallon JT et al. The selective peroxisomal proliferator-activated receptor-γ agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 43, 464-473 (2004).